Tech Transfer eNews Blog
University-Industry Engagement Advisor

Aprotum signs option agreement with Yale U to advance novel immunomodulators


By Jesse Schwartz
Published: April 27th, 2021

Clinical stage biopharma company Aptorum Group has entered into a material transfer and option agreement with Yale University to advance a group of novel, preclinical stage immunomodulators.

Developed by Yale researchers, the immunomodulators could potentially target autoimmune and oncology diseases such as rheumatoid arthritis, lupus, sclerosis and a range of cancers.

Under the agreement, Aptorum will be responsible for assessing the modulators against these diseases and others. Upon exercising its option to license, the company will begin the development and commercialization process on one or more of the immunomodulators.

“Aptorum believes that these immunomodulators have the potential to advance first-in-class drug discovery and development of such drugs for potential autoimmune and oncology diseases in particular,” says Ian Huen, CEO of Aptorum. “Through this initiative, we are looking forward to strategically expanding our development footprint in the treatment of those diseases, which have other potential applications such as in oncology and infectious diseases which are already core focuses of our company.”

Source: Business Wire

Global Coronavirus Partnering is a new research report providing the full collection of coronavirus deals signed between the world’s pharmaceutical and biotechnology companies. Details include financial deal terms overall headline values, upfront payments, milestones and royalties. Click here for details.

Posted under: Tech Transfer e-News

Twitter Facebook Linkedin Pinterest Email

No Comments so far ↓

There are no comments yet...Kick things off by filling out the form below.

Leave a Comment